Global Cancer Gene Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Cancer Gene Therapy Market is presumed to reach the market size of nearly USD 16.1 Billion by 2032 from USD 3.11 Billion in 2023 with a CAGR of 20.05% under the study period 2024 - 2032.

Cancer gene therapy uses genetic techniques to treat cancer by targeting specific genes or cellular pathways involved in tumor growth, progression, and survival. This therapeutic approach aims to modify or suppress cancer-related genes, stimulate immune responses against cancer cells, or deliver therapeutic genes directly into tumors to inhibit their growth or induce cell death. This therapy holds promise as a potential treatment option for various types of cancer, including solid tumors and hematological malignancies, offering the potential for targeted and personalized interventions with reduced toxicity compared to traditional chemotherapy and radiation therapy.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide and the limited efficacy of conventional cancer treatments drive the demand for novel therapeutic approaches such as gene therapy, which offers the potential for targeted and precise treatment of cancer at the genetic level. With the growing understanding of cancer biology, tumor heterogeneity, and molecular mechanisms of oncogenesis, there is an increasing emphasis on developing gene therapy strategies that target specific genetic mutations, oncogenes, and signaling pathways implicated in cancer progression. Additionally, the advent of gene editing technologies such as CRISPR/Cas9, TALENs, and zinc finger nucleases enables precise modification of cancer-related genes, offering new opportunities for developing gene therapies that disrupt oncogenic pathways, enhance tumor suppression, and improve patient outcomes.

Moreover, the increasing availability of viral and non-viral vectors for gene delivery, advancements in vector engineering, and optimization of gene transfer techniques drive the development of safer, more efficient, and targeted cancer gene therapy. Furthermore, the growing investment in cancer research, clinical trials, and regulatory clearances for gene therapy products foster innovation and commercialization in the cancer gene therapy market. With the potential to revolutionize cancer treatment paradigms, gene therapy provides new hope for patients with refractory cancers, rare genetic disorders, and unmet medical needs, driving interest and investment in this rapidly evolving field.

However, stringent regulatory requirements, clinical trial complexities, and ethical concerns may challenge the growth of the cancer gene therapy market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer gene therapy. The growth and trends of cancer gene therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cancer gene therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy

Oncolytic Virotherapy
Gene Induced Immunotherapy
Gene Transfer

By End-Use

Research Institutes
Biopharmaceutical Companies
Diagnostic Centers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Gene Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Gene Therapy market include Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., Merck KGaA, OncoGenex Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114339

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER GENE THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY THERAPY

5.1. Overview By Therapy
5.2. Historical and Forecast Data
5.3. Analysis By Therapy
5.4. Oncolytic Virotherapy Historic and Forecast Sales By Regions
5.5. Gene Induced Immunotherapy Historic and Forecast Sales By Regions
5.6. Gene Transfer Historic and Forecast Sales By Regions

6. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Research Institutes Historic and Forecast Sales By Regions
6.5. Biopharmaceutical Companies Historic and Forecast Sales By Regions
6.6. Diagnostic Centers Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CANCER GENE THERAPY COMPANIES

8.1. Cancer Gene Therapy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CANCER GENE THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abeona Therapeutics Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Asklepios BioPharmaceutical Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Altor Bioscience Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Bluebird Bio Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. BioCancell Inc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Celgene Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Elevate Bio Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. GlaxoSmithKline Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Genelux Corporation
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. GenVec
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. Introgen Therapeutics Inc.
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Merck KGaA
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. OncoGenex Pharmaceuticals Inc.
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies